Full Text View
Tabular View
No Study Results Posted
Related Studies
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
This study is ongoing, but not recruiting participants.
Study NCT00483067   Information provided by M.D. Anderson Cancer Center
First Received: June 5, 2007   Last Updated: June 6, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Additional conditions recognized in this trial
Hypereosinophilic Syndrome
Syndrome
More general conditions related to this trial
Disease
Eosinophilia
Hematologic Diseases
Leukocyte Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Interventions listed in this trial
2-CdA
Ara-C
G-CSF
Additional drug interventions recognized in this trial
2-chloro-3'-deoxyadenosine
Cladribine
Cytarabine
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services